Results 11 to 20 of about 7,763 (163)

Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria. [PDF]

Br J Clin Pharmacol
Aims Resistance to the artemisinins and the artemisinin‐based combination therapy (ACT) partner drugs has developed in Southeast Asia, and artemisinin resistance has also emerged in eastern Africa. Triple ACTs (triple artemisinin‐based combination therapies, TACT), consisting of two partner drugs with different mechanisms of action and similar ...
Ding J, Hoglund RM, van der Pluijm RW, Callery JJ, Peto TJ, Tripura R, Das S, Châu NH, Promnarate C, Mukaka M, Dysoley L, Fanello C, Onyamboko MA, Anvikar AR, Mayxay M, Smithuis F, von Seidlein L, Dhorda M, Amaratunga C, Faiz MA, Nghia HDT, White NJ, Day NPJ, Dondorp AM, Tarning J.   +24 more
europepmc   +2 more sources

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

PLoS ONE, 2017
BackgroundThe antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV.
Liusheng Huang, Vincent Carey, Jane C Lindsey, Florence Marzan, David Gingrich, Bobbie Graham, Linda Barlow-Mosha, Phionah K Ssemambo, Portia Kamthunzi, Sharon Nachman, Sunil Parikh, Francesca T Aweeka, IMPAACT P1079 protocol team   +12 more
doaj   +1 more source

Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial

Malaria Journal, 2018
Background Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in ...
Johanna M. Roth, Patrick Sawa, Nicodemus Makio, George Omweri, Victor Osoti, Selpha Okach, Felix Choy, Henk D. F. H. Schallig, Pètra Mens   +8 more
doaj   +1 more source

Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific region: a noninferiority trial

Revista da Sociedade Brasileira de Medicina Tropical, 2012
INTRODUCTION: In Colombia, there are no published studies for the treatment of uncomplicated Plasmodium falciparum malaria comparing artemisinin combination therapies.
Fernando De la Hoz Restrepo, Alexandra Porras Ramírez, Alejandro Rico Mendoza, Freddy Córdoba, Diana Patricia Rojas   +4 more
doaj   +1 more source

Therapeutic failure after regimen with artemether-lumefantrine combination therapy: a report of three cases in Benin City, Nigeria

Revista da Sociedade Brasileira de Medicina Tropical, 2019
Artemisinin-based combination therapy (ACT) is recommended by the World Health Organization for the treatment of uncomplicated malaria. Currently, there appears to be a downward trend in the efficacy of ACT in some parts of sub-Saharan Africa because ...
Osamudiamen Ebohon, Francis Irabor, Linda Osahon Ebohon, Ehimwenma Sheena Omoregie   +3 more
doaj   +1 more source

Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients

Journal of Infection in Developing Countries, 2013
Introduction: The distribution of both malaria and schistosomiasis exhibits a large geographical overlap in tropical environments, particularly in sub-Saharan Africa. This part of the world currently harbours more than 85% of the estimated global burden
Solomon M Abay, Mulugeta Tilahun, Nigus Fikrie, Abiy Habtewold   +3 more
doaj   +1 more source

A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya

Malaria Journal, 2008
Background Artemether/lumefantrine (AL) has been adopted as the treatment of choice for uncomplicated malaria in Kenya and other countries in the region.
Akhwale Willis S, Obonyo Charles O, Juma Elizabeth A, Ogutu Bernhards R   +3 more
doaj   +1 more source

Electrocardiographic safety evaluation of extended artemether-lumefantrine treatment in patients with uncomplicated Plasmodium falciparum malaria in Bagamoyo District, Tanzania

Malaria Journal, 2020
Background Extended artemisinin-based combination therapy (ACT) for treatment of uncomplicated Plasmodium falciparum malaria with already existing drug regimens, such as artemether-lumefantrine, might be effective in tackling the emerging ACT resistance.
Lwidiko E. Mhamilawa, Sven Wikström, Bruno P. Mmbando, Billy Ngasala, Andreas Mårtensson   +4 more
doaj   +1 more source

Formulation, process development and evaluation of artemether and lumefantrine soft gelatin capsule

Journal of Pharmacy and Bioallied Sciences, 2012
Artemether and Lumefantrine capsules are indicated for the treatment of P. falciparum malaria cases resistant to both chloroquine and sulphadoxine, pyrimethamine combination. Both artemether and lumefantrine act as blood schizontocides.
A Patel, A Lodha, J Chaudhuri, P Jadia, T Joshi, J Dalal   +5 more
doaj   +1 more source

Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change

The Pan African Medical Journal, 2020
INTRODUCTION: Artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) are the first line therapy of uncomplicated malaria in Burkina Faso. We assessed the treatment efficacy, tolerability of these drugs 11 years following its adoption as first ...
Issaka Zongo, Yves Daniel Compaoré, Frédéric Nikiéma, Moussa Zongo, Nouhoun Barry, Fabrice Anyirékun Somé, Naomie Kaboré, Jean Bosco Ouédraogo   +7 more
doaj   +1 more source